BAMBEVI 100 MG / 4 ML
BEVACIZUMAB : 100 MG / 4 ML · DIN 02520729 · APOTEX INC
Health Canada status: MARKETED
What is BAMBEVI?
BAMBEVI 100 MG / 4 ML contains BEVACIZUMAB : 100 MG / 4 ML. It is listed in the Health Canada Drug Product Database under DIN 02520729, held by APOTEX INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 09-Nov-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BAMBEVI used for?
Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Platinum-Sensitive/Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; Malignant Glioma (Glioblastoma).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02520729 |
|---|---|
| Brand name | BAMBEVI |
| Generic / active ingredient | BEVACIZUMAB : 100 MG / 4 ML |
| Manufacturer | APOTEX INC |
| Strength | 100 MG / 4 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01FG01 BEVACIZUMAB |
| Biosimilar | Yes |
| Health Canada status | MARKETED |
| Status date | 09-Nov-2021 |
How is it administered?
Administered as IV infusion. Initial dose over 90 min; if tolerated, second over 60 min; then 30 min. Dose varies by indication (5-15 mg/kg) every 2 or 3 weeks. Continue until disease progression.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 2-8°C. Do not freeze. Keep vial in outer carton to protect from light. (Note: General biologic storage inferred from standard bevacizumab monographs).
How is it supplied?
Single-use, preservative-free, clear glass vials with butyl rubber stopper. Packs of 1 vial.
Contraindications
Hypersensitivity to bevacizumab, CHO cell products, or other recombinant antibodies; untreated Central Nervous System (CNS) metastases.
Warnings and precautions
Serious risks of GI perforation, wound healing complications, and severe hemorrhage. Risk of hypertension, arterial thromboembolism, and congestive heart failure. Not for intravitreal use.
What can be used instead?
Other Canadian products sharing ATC code L01FG01 BEVACIZUMAB. 13 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ABEVMY | 100 MG / 4 ML | SOLUTION | BIOSIMILAR COLLABORATIONS IRELAND LIMITED | MARKETED | DIN 02522179 |
| ABEVMY | 400 MG / 16 ML | SOLUTION | BIOSIMILAR COLLABORATIONS IRELAND LIMITED | MARKETED | DIN 02522160 |
| AVASTIN | 25 MG | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02270994 |
| AYBINTIO | 100 MG / 4 ML | SOLUTION | SAMSUNG BIOEPIS CO., LTD | MARKETED | DIN 02522829 |
| AYBINTIO | 400 MG / 16 ML | SOLUTION | SAMSUNG BIOEPIS CO., LTD | MARKETED | DIN 02522837 |
| BAMBEVI | 400 MG / 16 ML | SOLUTION | APOTEX INC | MARKETED | DIN 02520737 |
| MVASI | 25 MG | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02470756 |
| MVASI | 25 MG | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02470748 |
| VEGZELMA | 100 MG / 4 ML | SOLUTION | CELLTRION INC. | MARKETED | DIN 02534177 |
| VEGZELMA | 400 MG / 16 ML | SOLUTION | CELLTRION INC. | MARKETED | DIN 02534185 |
Who else supplies BEVACIZUMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BEVACIZUMAB appears in 120 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.